Abstract
Danhong injection (DHI) has been widely in the treatment of chronic heart failure (CHF) in China; however, there is not enough clinical evidence DHI for treating CHF. Two researchers will search literatures of DHI for CHF in databases. Extracted data are analyzed with Review Manager 5.3 software. The selected studies should be conducted quality evaluation, forest plots and funnel plots will be run by RevMan5.3. This systematic review validates the clinical efficacy and safety of DHI in the treatment of CHF through the analysis of New York Heart Association functional classification, left ventricular ejection fraction, left ventricular end-diastolic dimension, cardiac output, brain natriuretic peptide, adverse events. This systematic review will be provided a rational clinical evidence to evaluate the effectiveness and safety of DHI for the treatment of CHF. PROSPERO CRD42019144686.
Highlights
Chronic heart failure (CHF) is one of the most common chronic diseases in the world and it has exerted great economic pressure on the public medical system.[1,2] Patients with chronic heart failure (CHF) experience a substantial reduction in their quality of life and increased risk for premature death
Danhong injection (DHI) is a Chinese drug used for coronary heart disease, angina pectoris, myocardial infarction, pulmonary heart disease, and cerebral infarction.[4]
DHI is composed of Danshen and Honghua, and the major active ingredients are tanshinone, salvianolic acid, safflower yellow pigment, phenol glycosides, and catechol
Summary
This systematic review validates the clinical efficacy and safety of DHI in the treatment of CHF through the analysis of New York Heart Association functional classification, left ventricular ejection fraction, left ventricular end-diastolic dimension, cardiac output, brain natriuretic peptide, adverse events
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.